P2RY12 and acute coronary syndrome: According to ESC 2023 guidelines for the management of acute coronary syndrome, pre-treatment (P2Y12 administration before angiography when coronary anatomy is unknown) with P2Y12 inhibitor may be considered in STEMI and NSTE-ACS with delayed invasive angiography (>24 h), but is not recommended for NSTE-ACS with early invasive angiography (<24 h) strategy [19].